Baxter International (NYSE:BAX) Announces Earnings Results, Beats Estimates By $0.06 EPS

Key Points

• Baxter beat quarterly expectations: Adjusted EPS was $0.58 versus the $0.52 consensus, while revenue rose 5% year over year to $2.98 billion, surpassing estimates.
• Management raised its outlook and improved cash flow: Baxter increased its 2026 organic sales-growth forecast to 3%-4%, raised the low end of adjusted EPS guidance to $2.05-$2.15, and reported $448 million in quarterly free cash flow.
• Risks remain despite the earnings beat: EPS declined from $0.69 a year earlier, the company maintains a negative net margin, and shares fell 7.8% as investors weighed the discontinuation of cephalosporin production and expected 2027 headwinds.

Baxter International (NYSE:BAX - Get Free Report) released its earnings results on Thursday. The medical instruments supplier reported $0.58 earnings per share for the quarter, beating the consensus estimate of $0.52 by $0.06, FiscalAI reports. Baxter International had a positive return on equity of 16.57% and a negative net margin of 9.27%. The company had revenue of $2.98 billion for the quarter, compared to the consensus estimate of $2.91 billion. During the same period in the previous year, the business earned $0.69 earnings per share. Baxter International's quarterly revenue was up 5.0% compared to the same quarter last year.

Here are the key takeaways from Baxter International's conference call:

• Third-quarter results exceeded expectations: Sales rose 5% organically to approximately $3 billion, with broad-based growth led by Advanced Surgery, drug compounding, and infusion systems. Baxter raised its 2026 organic sales growth outlook to 3%-4% and lifted the low end of adjusted EPS guidance to $2.05-$2.15.
• Cash flow and deleveraging improved: Third-quarter free cash flow was $448 million, bringing year-to-date free cash flow to $705 million. Baxter also completed a $600 million tender offer that retired $854 million of debt and remains confident in reaching approximately 3x net leverage by year-end.
• Operational improvements continued across the portfolio, including better on-time shipments, improved quality metrics, cost savings, and more than 700 Baxter GPS continuous-improvement initiatives completed year to date. Advanced Surgery grew 12%, while HST margins expanded 140 basis points.
• Quality and portfolio actions create near-term pressure: Baxter will discontinue cephalosporin production at its Round Lake facility following supply and FDA warning-letter issues; the products are expected to contribute approximately $50 million in 2026 sales and $30 million in operating income. Management also flagged 2027 headwinds from product exits, the loss of tariff-refund benefits, inflation, tariffs, and the end of Vantive-related TSA services.

Baxter International Trading Down 7.8%

BAX traded down $2.00 on Thursday, reaching $23.46. 11,889,629 shares of the company traded hands, compared to its average volume of 7,800,397. The company has a market cap of $12.13 billion, a P/E ratio of -11.42, a price-to-earnings-growth ratio of 3.83 and a beta of 0.65. The company has a quick ratio of 1.32, a current ratio of 1.95 and a debt-to-equity ratio of 1.39. Baxter International has a one year low of $15.73 and a one year high of $30.00. The firm has a fifty day simple moving average of $24.72 and a two-hundred day simple moving average of $21.34.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on BAX. The Goldman Sachs Group lifted their target price on Baxter International from $19.00 to $21.00 and gave the stock a "neutral" rating in a report on Wednesday, July 15th. Barclays initiated coverage on Baxter International in a report on Wednesday, October 7th. They set an "underweight" rating and a $20.00 price target for the company. TD Cowen lifted their price objective on Baxter International from $20.00 to $24.00 and gave the stock a "hold" rating in a research note on Monday, July 27th. Citigroup decreased their price objective on Baxter International from $28.00 to $27.00 and set a "neutral" rating on the stock in a report on Monday, October 5th. Finally, Zacks Research upgraded Baxter International from a "strong sell" rating to a "hold" rating in a research report on Tuesday, August 11th. One analyst has rated the stock with a Buy rating, ten have issued a Hold rating and three have issued a Sell rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Reduce" and an average target price of $21.73.

Key Baxter International News

Here are the key news stories impacting Baxter International this week:

• Positive Sentiment: Quarterly results exceeded expectations: Baxter reported adjusted earnings of $0.58 per share, above the $0.51–$0.52 consensus range, while revenue of $2.98 billion surpassed estimates of approximately $2.91 billion. Revenue increased 5% from the prior year. Baxter International Q3 Earnings and Revenues Surpass Estimates
• Positive Sentiment: Growth was broad-based: Segment-wide sales growth helped drive the quarterly beat, and management raised its 2026 financial outlook, providing a more constructive forward-looking signal for investors. Baxter Q3 Earnings Beat and 2026 Outlook Raised
• Positive Sentiment: Baxter also declared its regular quarterly dividend, supporting the stock’s income appeal. Baxter Raises Guidance and Declares Dividend
• Neutral Sentiment: The results indicate improving sales momentum, but investors will likely look for details on the revised 2026 outlook and whether growth can translate into stronger profitability.
• Negative Sentiment: Profitability remains a concern: Quarterly EPS declined from $0.69 a year earlier to $0.58, while Baxter continued to report a negative net margin. Analysts and investors may be discounting the earnings beat because cost and margin pressures remain unresolved. Baxter Reports Third-Quarter 2026 Results

About Baxter International

Baxter International Inc is a global medical products and healthcare technology company headquartered in Deerfield, Illinois. The company develops, manufactures and distributes products used in hospitals, clinics, ambulatory care centers and other healthcare settings.

Baxter's portfolio has included intravenous therapies and administration systems, infusion pumps, connected-care technologies, surgical products, patient monitoring equipment and products used in medication preparation and delivery.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.